N-(2-Morpholin-4-yl-ethyl)-succinamic acid 3-(9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)-4-oxo-3,4-dihydro-quinazolin-2-yl-methyl ester | 215105-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(2-Morpholin-4-yl-ethyl)-succinamic acid 3-(9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)-4-oxo-3,4-dihydro-quinazolin-2-yl-methyl ester
• 英文别名: [3-(6-Methyl-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl)-4-oxoquinazolin-2-yl]methyl 4-(2-morpholin-4-ylethylamino)-4-oxobutanoate
• CAS: 215105-13-8
• 化学式: C₃₇H₃₈N₆O₆
• 分子量: 662.745
• InChiKey: APNVRRQKEXFREY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  49
• 可旋转键数：
  11
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  133
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Pharmaceutical composition for preventing or treating a disease associated with an excess of IL-12-production
  申请人：——

  公开号：US20020119967A1

  公开（公告）日：2002-08-29

  This invention relates to the use of a PDE4 inhibitor or a pharmacologically acceptable salt thereof for manufacturing a medicament for preventing or treating a disease associated with an excess in IL-12 production.

  本发明涉及使用PDE4抑制剂或其药理学上可接受的盐来制造用于预防或治疗与IL-12过度产生相关的疾病的药物。
• Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1199074A1

  公开（公告）日：2002-04-24

  This invention relates to the use of a PDE4 inhibitor or a pharmacologically acceptable salt thereof for manufacturing a medicament for preventing or treating a disease associated with an excess in IL-12 production.

  本发明涉及使用 PDE4 抑制剂或其药理上可接受的盐制造药物，以预防或治疗与 IL-12 生成过多有关的疾病。
• PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES
  申请人：Pfizer Holding France

  公开号：EP0980374B1

  公开（公告）日：2003-02-12
• US6239130B1
  申请人：——

  公开号：US6239130B1

  公开（公告）日：2001-05-29